|
515 Companies |
|
302 Products |
|
302 Products |
|
167 Mechanisms of Action |
|
1404 Trials |
|
125634 News |
|
| «12...15141515151615171518151915201521152215231524...15771578» |
- ||||||| Halaven (eribulin mesylate) / Eisai
Trial completion: Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma (clinicaltrials.gov) - Oct 21, 2016
P3, N=452, Completed, Sponsor: Eisai Inc.
Active, not recruiting --> Completed
- Ibrance (palbociclib) / Pfizer
Trial suspension: Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors (clinicaltrials.gov) - Oct 21, 2016
P1, N=40, Suspended, Sponsor: Pediatric Brain Tumor Consortium
Active, not recruiting --> Completed Recruiting --> Suspended
- New trial, Discordant: CERTUM: Concordance Between Sonography Amd MRI for Presurgical Diagnosis of Uterine Mesenchymal Malignant Tumors (clinicaltrials.gov) - Oct 19, 2016
P=N/A, N=50, Not yet recruiting, Sponsor: Fundaci
- | aldoxorubicin (INNO-206) / ImmunityBio
Trial completion, Enrollment change: A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma (clinicaltrials.gov) - Oct 19, 2016
P2, N=16, Completed, Sponsor: CytRx
Recruiting --> Suspended Active, not recruiting --> Completed | N=30 --> 16
- ||| aldoxorubicin (INNO-206) / ImmunityBio
Enrollment change, Trial primary completion date, Metastases: Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Oct 19, 2016
P1/2, N=80, Recruiting, Sponsor: CytRx
Active, not recruiting --> Completed | N=30 --> 16 N=30 --> 80 | Trial primary completion date: Dec 2016 --> Dec 2018
- Xofigo (radium Ra-223 dichloride) / Bayer
Trial primary completion date: Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma (clinicaltrials.gov) - Oct 19, 2016
P1/2, N=15, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
N=30 --> 80 | Trial primary completion date: Dec 2016 --> Dec 2018 Trial primary completion date: Oct 2017 --> Oct 2018
- Actimmune (interferon gamma-1 b) / Clinigen, Amgen
Trial primary completion date, IO biomarker: Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma (clinicaltrials.gov) - Oct 18, 2016
P=N/A, N=12, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Oct 2017 --> Oct 2018 Trial primary completion date: Apr 2017 --> Oct 2017
- || saracatinib (AZD0530) / AstraZeneca
Trial primary completion date: A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung (clinicaltrials.gov) - Oct 14, 2016
P2, N=88, Active, not recruiting, Sponsor: Sarcoma Alliance for Research through Collaboration
Trial primary completion date: Apr 2017 --> Oct 2017 Trial primary completion date: Sep 2014 --> Dec 2016
- Trial initiation date, CAR T-Cell Therapy, Lymphopenia: ExCeL: EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma (clinicaltrials.gov) - Oct 14, 2016
P1, N=48, Not yet recruiting, Sponsor: Gary Archer Ph.D.
Trial primary completion date: Sep 2014 --> Dec 2016 Initiation date: Jun 2016 --> Dec 2016
- || dasatinib / Generic mfg.
Trial primary completion date, Metastases: Trial of Dasatinib in Advanced Sarcomas (clinicaltrials.gov) - Oct 13, 2016
P2, N=386, Active, not recruiting, Sponsor: Sarcoma Alliance for Research through Collaboration
Initiation date: Jun 2016 --> Dec 2016 Trial primary completion date: Jun 2015 --> Dec 2016
- Avastin (bevacizumab) / Roche
Trial primary completion date, Combination therapy: SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors (clinicaltrials.gov) - Oct 13, 2016
P2, N=25, Active, not recruiting, Sponsor: Sarcoma Alliance for Research through Collaboration
Trial primary completion date: Jun 2015 --> Dec 2016 Trial primary completion date: Sep 2016 --> Jun 2017
- |||| Varubi (rolapitant oral) / TerSera Therap, GSK
Enrollment open, Trial initiation date, Trial primary completion date: Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving Chemotherapy (clinicaltrials.gov) - Oct 13, 2016
P2, N=91, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Sep 2016 --> Jun 2017 Not yet recruiting --> Recruiting | Initiation date: Jul 2016 --> Oct 2016 | Trial primary completion date: Jul 2019 --> Oct 2019
- Biomarker, New trial, Stroma: Serum Dickkopf-4 as a Biomarker for the Diagnosis and Treatment of Gastrointestinal Stromal Tumor (clinicaltrials.gov) - Oct 13, 2016
P=N/A, N=50, Recruiting, Sponsor: RenJi Hospital
- New P1/2 trial, Metastases: MITIGATE-NeoBOM: A Study to Evaluate 68Ga- NeoBOMB1 in Patients With Advanced TKI-treated GIST Using PET/CT (clinicaltrials.gov) - Oct 13, 2016
P1/2, N=12, Not yet recruiting, Sponsor: Medical University Innsbruck
- Avastin (bevacizumab) / Roche
Trial primary completion date: Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma (clinicaltrials.gov) - Oct 12, 2016
P2, N=182, Active, not recruiting, Sponsor: Radiation Therapy Oncology Group
Not yet recruiting --> Recruiting | Initiation date: Jul 2016 --> Oct 2016 | Trial primary completion date: Jul 2019 --> Oct 2019 Trial primary completion date: Jul 2016 --> Mar 2018
- Trial primary completion date, Surgery, Metastases: STRASS: Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma (clinicaltrials.gov) - Oct 12, 2016
P3, N=256, Recruiting, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Trial primary completion date: Jul 2016 --> Mar 2018 Trial primary completion date: Jan 2019 --> Jan 2017
- Votrient (pazopanib) / Novartis, BeiGene
Enrollment change, Trial withdrawal, Metastases: Study of Pazopanib Versus Placebo as Maintenance Therapy for Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Oct 12, 2016
P2, N=0, Withdrawn, Sponsor: GlaxoSmithKline
Trial primary completion date: Jan 2019 --> Jan 2017 N=188 --> 0 | Not yet recruiting --> Withdrawn
- Votrient (pazopanib) / Novartis, BeiGene
Trial primary completion date, Metastases: Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer (clinicaltrials.gov) - Oct 11, 2016
P2, N=39, Recruiting, Sponsor: Mayo Clinic
N=188 --> 0 | Not yet recruiting --> Withdrawn Trial primary completion date: May 2016 --> May 2017
- Trial primary completion date, Surgery, Biopsy: Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma (clinicaltrials.gov) - Oct 11, 2016
P=N/A, N=30, Active, not recruiting, Sponsor: Mayo Clinic
Trial primary completion date: May 2016 --> May 2017 Trial primary completion date: Jul 2016 --> Jul 2017
- || Ibrance (palbociclib) / Pfizer
Trial primary completion date, Metastases: PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma (clinicaltrials.gov) - Oct 11, 2016
P2, N=86, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Jul 2016 --> Jul 2017 Trial primary completion date: Sep 2016 --> Sep 2017
- Trial primary completion date, HEOR: Survivorship Care in Reducing Symptoms in Young Adult Cancer Survivors (clinicaltrials.gov) - Oct 11, 2016
P=N/A, N=455, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Sep 2016 --> Sep 2017 Trial primary completion date: Mar 2017 --> Oct 2017
- sorafenib / Generic mfg.
Trial primary completion date, Surgery: Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma (clinicaltrials.gov) - Oct 11, 2016
P2, N=20, Recruiting, Sponsor: OHSU Knight Cancer Institute
Trial primary completion date: Mar 2017 --> Oct 2017 Trial primary completion date: Oct 2016 --> Oct 2017
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, IO biomarker, Metastases: Vaccine Therapy in Treating Patients With Metastatic Solid Tumors (clinicaltrials.gov) - Oct 11, 2016
P1, N=36, Recruiting, Sponsor: Pravin Kaumaya
Trial primary completion date: Oct 2016 --> Oct 2017 Trial primary completion date: Dec 2016 --> Dec 2017
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial termination, Trial primary completion date: T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant (clinicaltrials.gov) - Oct 11, 2016
P2, N=34, Terminated, Sponsor: St. Jude Children's Research Hospital
Trial primary completion date: Dec 2016 --> Dec 2017 Recruiting --> Terminated | Trial primary completion date: Aug 2018 --> Dec 2015; Study was terminated in August 2016 due to replacement by a new study.
- |||||||||| Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
New P3 trial, Metastases: Trabectedin Maintenance Post 1st-line in STS (clinicaltrials.gov) - Oct 11, 2016
P3, N=90, Not yet recruiting, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
- ||| ontorpacept intratumoral (TTI 621 intratumoral) / Pfizer
Enrollment open: Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides (clinicaltrials.gov) - Oct 6, 2016
P1, N=54, Recruiting, Sponsor: Trillium Therapeutics Inc.
Recruiting --> Terminated | Trial primary completion date: Aug 2018 --> Dec 2015; Study was terminated in August 2016 due to replacement by a new study. Not yet recruiting --> Recruiting
- Enrollment open, Enrollment change, CAR T-Cell Therapy: CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII (clinicaltrials.gov) - Oct 6, 2016
P1/2, N=107, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Suspended --> Recruiting | N=18 --> 107
- decitabine / Generic mfg.
Trial completion: Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma (clinicaltrials.gov) - Oct 6, 2016
P1, N=19, Completed, Sponsor: University of Louisville
Suspended --> Recruiting | N=18 --> 107 Active, not recruiting --> Completed
- dasatinib / Generic mfg.
Enrollment change: PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative (clinicaltrials.gov) - Oct 6, 2016
P1, N=20, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Active, not recruiting --> Completed N=30 --> 20
- ||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Enrollment closed, Combination therapy, Metastases: A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas (clinicaltrials.gov) - Oct 6, 2016
P2, N=60, Active, not recruiting, Sponsor: Massachusetts General Hospital
N=30 --> 20 Recruiting --> Active, not recruiting
- Imlygic (talimogene laherparepvec) / Amgen
New P2 trial, IO biomarker, Surgery: Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery (clinicaltrials.gov) - Oct 5, 2016
P2, N=40, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- ||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P2 trial, PD(L)-1 Biomarker, IO biomarker: A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers (clinicaltrials.gov) - Oct 5, 2016
P2, N=60, Not yet recruiting, Sponsor: Olivia Newton-John Cancer Research Institute
- imatinib / Generic mfg.
New P2 trial, Stroma, Metastases: SSG XXV: The Stop-GIST Trial; Discontinuation of Imatinib in Patients With Oligo-metastatic GIST (clinicaltrials.gov) - Oct 4, 2016
P2, N=31, Not yet recruiting, Sponsor: Oslo University Hospital
- || Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche
Preclinical, Trial primary completion date, Metastases: A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma (clinicaltrials.gov) - Oct 4, 2016
P2, N=208, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Trial primary completion date: Oct 2020 --> May 2021
- sirolimus / Generic mfg.
Trial completion, Enrollment change: Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors (clinicaltrials.gov) - Oct 4, 2016
P1, N=18, Completed, Sponsor: Roswell Park Cancer Institute
Trial primary completion date: Oct 2020 --> May 2021 Active, not recruiting --> Completed | N=30 --> 18
- LPX EWS/FL1 T1 / Gradalis
Enrollment open, Metastases: Pbi-shRNA (clinicaltrials.gov) - Oct 3, 2016
P1, N=22, Recruiting, Sponsor: Strike Bio, Inc.
Active, not recruiting --> Completed | N=30 --> 18 Not yet recruiting --> Recruiting
- |||| Rintega (rindopepimut) / Celldex
Trial completion, Enrollment change: A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma (clinicaltrials.gov) - Oct 3, 2016
P2, N=127, Completed, Sponsor: Celldex Therapeutics
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | N=168 --> 127
- Torisel (temsirolimus) / Pfizer
Trial suspension: Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma (clinicaltrials.gov) - Oct 3, 2016
P3, N=387, Suspended, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | N=168 --> 127 Recruiting --> Suspended
- |||| ontuxizumab (MORAb-004) / Eisai
Trial completion, Metastases: Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation (clinicaltrials.gov) - Sep 30, 2016
P2, N=209, Completed, Sponsor: Morphotek
Recruiting --> Suspended Active, not recruiting --> Completed
- Trial initiation date: THEODORA: Tumour and HEalthy Tissues DOse-response and Radiosensitivity Assay (clinicaltrials.gov) - Sep 30, 2016
P=N/A, N=100, Not yet recruiting, Sponsor: Centre Leon Berard
Active, not recruiting --> Completed Initiation date: Jul 2016 --> Oct 2016
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Combination therapy, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker: Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas (clinicaltrials.gov) - Sep 29, 2016
P1/2, N=352, Recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Jul 2016 --> Oct 2016 Trial primary completion date: Nov 2016 --> Oct 2020
- Avastin (bevacizumab) / Roche
Enrollment closed, Metastases: Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers (clinicaltrials.gov) - Sep 29, 2016
P1, N=36, Active, not recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Nov 2016 --> Oct 2020 Recruiting --> Active, not recruiting
- Trial completion, Enrollment change, Trial primary completion date, Surgery, Stroma: Surgery in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor (clinicaltrials.gov) - Sep 28, 2016
P2, N=6, Completed, Sponsor: Translational Research Informatics Center, Kobe, Hyogo, Japan
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=44 --> 6 | Trial primary completion date: Sep 2014 --> Mar 2016
- imatinib / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date, Stroma: Imatinib Mesylate in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor (clinicaltrials.gov) - Sep 28, 2016
P2, N=5, Completed, Sponsor: Translational Research Informatics Center, Kobe, Hyogo, Japan
Active, not recruiting --> Completed | N=44 --> 6 | Trial primary completion date: Sep 2014 --> Mar 2016 Active, not recruiting --> Completed | N=37 --> 5 | Trial primary completion date: Sep 2014 --> Mar 2016
- || Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma
Trial primary completion date, Metastases: YonSar: Efficacy and Safety of Trabectedin (Yondelis (clinicaltrials.gov) - Sep 28, 2016
P=N/A, N=100, Recruiting, Sponsor: PharmaMar, Spain
Active, not recruiting --> Completed | N=37 --> 5 | Trial primary completion date: Sep 2014 --> Mar 2016 Trial primary completion date: Dec 2016 --> Jan 2018
- Trial primary completion date: Collection of Tissue & Blood From Patients w/ Benign & Malignant Tumors of the Soft Tissue & Gastrointestinal Tract (clinicaltrials.gov) - Sep 27, 2016
P=N/A, N=6000, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Dec 2016 --> Jan 2018 Trial primary completion date: Dec 2016 --> Dec 2017
- ||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Enrollment open, Combination therapy, Metastases: PM1183-A-014-15: Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors (clinicaltrials.gov) - Sep 21, 2016
P1, N=100, Recruiting, Sponsor: PharmaMar
Trial primary completion date: Dec 2016 --> Dec 2017 Not yet recruiting --> Recruiting
- |||| Tazverik (tazemetostat) / Eisai, Ipsen
Enrollment open: TRuST: A Study to Assess the Long-term Safety of Tazemetostat (clinicaltrials.gov) - Sep 21, 2016
P2, N=300, Recruiting, Sponsor: Epizyme, Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Votrient (pazopanib) / Novartis, BeiGene, sapanisertib (CB-228) / Calithera
Metastases: Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Sep 21, 2016
P2, N=148, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Suspended --> Recruiting
- ifosfamide / Generic mfg., docetaxel / Generic mfg., gemcitabine / Generic mfg.
Enrollment open, P2 data: OsteoREC2015: Phase II Trial for the Treatment of Relapsed Osteosarcoma (clinicaltrials.gov) - Sep 20, 2016
P2, N=100, Recruiting, Sponsor: Italian Sarcoma Group
Suspended --> Recruiting Not yet recruiting --> Recruiting